Detection and treatment of pancreatic, ovarian and other cancers
View Patent ↗The application provides methods of diagnosis, prognosis, prophylaxis and treatment of ovarian, pancreatic and other cancers using antibodies that specifically bind to denatured CD70.
1. A monoclonal antibody that specifically binds to denatured human CD70 on a sample of formalin fixed, paraffin-embedded cells or tissues that express human CD70, wherein the monoclonal antibody comprises three heavy chain complementarity determining regions (CDRs): heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3, wherein the heavy chain CDRs are identical to the heavy chain CDRs of the antibody SG-21.1C1; and three light chain CDRs: light chain CDR1, light chain CDR2, and light chain CDR3, wherein the light chain CDRs are identical to the light chain CDRs of the antibody SG-21.1C, and wherein the antibody SG-21.1C is produced by the hybridoma deposited with the ATCC and assigned Accession No. PTA-8733.
2. The monoclonal antibody of claim 1 , which is a chimeric or humanized antibody.
3. The monoclonal antibody of claim 1 , that is antibody SG-21.1C1 as produced by the hybridoma deposited with the ATCC and assigned Accession No. PTA-8733.
4. The monoclonal antibody of claim 1 , comprising the heavy chain variable region of the antibody SG-21.1C1 and light chain variable region of the antibody SG-21.1C1.
5. A diagnostic kit, comprising: the monoclonal antibody of claim 1 .
6. A method of detecting expression of CD70 in a tissue sample of a patient, comprising
obtaining a tissue sample of pancreas, ovary, lung, larynx, pharynx, breast, or skin from the patient;
fixing the tissue sample and denaturing CD70 in the tissue sample, wherein the sample is fixed in formalin and embedded in paraffin;
contacting the fixed tissue sample with the monoclonal antibody of claim 1 ; and
detecting binding of the monoclonal antibody to the fixed tissue sample to determine whether CD70 is expressed in the sample.
7. A combination diagnostic and pharmaceutical kit comprising the monoclonal antibody of claim 1 for use in diagnosis and an antibody that specifically binds to an extracellular domain of native of CD70 for use in therapy.
8. The monoclonal antibody of claim 1 , wherein the antibody binds to the extracellular domain of human CD70 protein.
9. The monoclonal antibody of claim 1 , wherein the antibody cross-reacts with a cynomolgous CD70 protein.